ES2530670T3 - Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo - Google Patents

Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo Download PDF

Info

Publication number
ES2530670T3
ES2530670T3 ES08711707T ES08711707T ES2530670T3 ES 2530670 T3 ES2530670 T3 ES 2530670T3 ES 08711707 T ES08711707 T ES 08711707T ES 08711707 T ES08711707 T ES 08711707T ES 2530670 T3 ES2530670 T3 ES 2530670T3
Authority
ES
Spain
Prior art keywords
same
pharmaceutical composition
amino acid
acid sequence
fgf23 antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08711707T
Other languages
English (en)
Inventor
Yuji Yamazaki
Itaru Urakawa
Hitoshi Yoshida
Yukiko Aono
Takeyoshi Yamashita
Takashi Shimada
Hisashi Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2530670(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ES2530670T3 publication Critical patent/ES2530670T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)

Abstract

Anticuerpo frente a FGF23 humano o un fragmento funcional del mismo frente a FGF23 humano, que comprende una secuencia de aminoácidos de cadena pesada que comprende una secuencia de aminoácidos desde Q en la posición 20 hasta S en la posición 136 de SEC ID Nº 12 y una secuencia de aminoácidos de cadena ligera que comprende una secuencia de aminoácidos desde A en la posición 23 hasta K en la posición 128 de SEC ID Nº 14.
ES08711707T 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo Active ES2530670T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007034018 2007-02-14
PCT/JP2008/052918 WO2008099969A1 (ja) 2007-02-14 2008-02-14 抗fgf23抗体及びそれを含む医薬組成物

Publications (1)

Publication Number Publication Date
ES2530670T3 true ES2530670T3 (es) 2015-03-04

Family

ID=39690189

Family Applications (3)

Application Number Title Priority Date Filing Date
ES12170984T Active ES2625823T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
ES08711707T Active ES2530670T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
ES17152168T Active ES2811318T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES12170984T Active ES2625823T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17152168T Active ES2811318T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo

Country Status (22)

Country Link
US (4) US7883705B2 (es)
EP (3) EP2128253B1 (es)
JP (1) JP4800396B2 (es)
KR (1) KR101462291B1 (es)
CN (2) CN101652476B (es)
AU (1) AU2008215346B2 (es)
CA (1) CA2677782C (es)
CY (3) CY1118835T1 (es)
DK (3) DK2128253T3 (es)
ES (3) ES2625823T3 (es)
FR (1) FR18C1032I2 (es)
HR (2) HRP20170548T1 (es)
HU (3) HUE031728T2 (es)
LT (3) LT2502996T (es)
LU (2) LUC00082I2 (es)
NL (1) NL300945I2 (es)
NO (1) NO2018025I1 (es)
PL (3) PL2502996T3 (es)
PT (3) PT2502996T (es)
SI (2) SI2502996T1 (es)
TW (1) TWI422593B (es)
WO (1) WO2008099969A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1310554B1 (en) * 2000-08-11 2010-05-26 Kyowa Hakko Kirin Co., Ltd. Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
CN100519584C (zh) * 2001-12-28 2009-07-29 麒麟医药株式会社 抗成纤维细胞生长因子23的抗体
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
EP2723391B1 (en) 2011-06-24 2018-06-13 University of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
HRP20251099T1 (hr) * 2014-06-09 2025-11-07 Ultragenyx Pharmaceutical Inc. Učinkovita i djelotvorna kontrola serumskog fosfata za optimalno stvaranje kostiju
WO2018069232A1 (en) 2016-10-10 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of having cardiac hypertrophy
EP3604517A4 (en) 2017-03-30 2020-12-16 Sysmex Corporation ANTI-APOA1 ANTIBODIES
JP2022527790A (ja) * 2019-03-29 2022-06-06 アターガ，エルエルシー 抗ｆｇｆ２３抗体分子
EP4570910A1 (en) 2022-08-10 2025-06-18 Kyowa Kirin Co., Ltd. Anti-fgf23 antibody, and fragment of said antibody
KR20250157441A (ko) * 2023-03-10 2025-11-04 울트라제닉스 파마수티컬 인코포레이티드 개선된 친화도 및 효능을 갖는 인간 fgf23-결합 항체
CN119080938B (zh) * 2023-06-05 2025-06-24 东莞市朋志生物科技有限公司 抗25羟维生素d抗体、检测25羟维生素d的试剂和试剂盒
CN119954951A (zh) * 2024-12-31 2025-05-09 上海良润生物医药科技有限公司 iFGF23特异性抗体及其在制备慢性肾病辅助诊断试剂中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
WO1985003934A1 (fr) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61178926U (es) 1985-04-23 1986-11-08
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5958879A (en) 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US20020102604A1 (en) 1999-12-08 2002-08-01 Milne Edwards Jean-Baptiste Dumas Full-length human cDNAs encoding potentially secreted proteins
ES2281964T3 (es) 1998-05-18 2007-10-01 University College London Hormona polipeptidica derivada de tumor humano fosfatonina.
TWI255853B (en) 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
WO2000060085A1 (en) 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
US6596849B1 (en) 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
JP2004522402A (ja) 1999-06-02 2004-07-29 ジェネンテック・インコーポレーテッド 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
CA2491610A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003518944A (ja) 2000-01-05 2003-06-17 ザイモジェネティクス，インコーポレイティド 新規ｆｇｆ相同体ｚｆｇｆ１２
AU2001239765A1 (en) 2000-02-14 2001-08-27 Smith Kline Beecham Corporation Novel compounds
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
CA2398603A1 (en) 2000-02-15 2001-08-23 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
JP2003531583A (ja) 2000-03-08 2003-10-28 カイロン コーポレイション ヒトｆｇｆ−２３遺伝子および遺伝子発現産物
US20030105302A1 (en) 2000-03-08 2003-06-05 Nobuyuki Itoh Human FGF-23 gene and gene expression products
JP2004504063A (ja) 2000-07-19 2004-02-12 アドバンスド　リサーチ　＆　テクノロジー　インスティテュート 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法
EP1310554B1 (en) 2000-08-11 2010-05-26 Kyowa Hakko Kirin Co., Ltd. Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
WO2002076467A1 (en) 2001-03-22 2002-10-03 Genzyme Corporation Compositions and methods to regulate bone and mineral metabolism
CA2443719A1 (en) 2001-04-26 2002-11-07 Geneprot, Inc. Human fibroblast growth factor-related compositions
CA2658221C (en) * 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
CN100519584C (zh) 2001-12-28 2009-07-29 麒麟医药株式会社 抗成纤维细胞生长因子23的抗体
US7094551B2 (en) 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
JPWO2004083425A1 (ja) * 2003-03-17 2006-06-22 麒麟麦酒株式会社 歯周病治療剤
CA2569509C (en) * 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
AU2005267720B2 (en) * 2004-08-05 2012-02-23 Genentech, Inc. Humanized anti-cmet antagonists
AU2005280975B2 (en) * 2004-09-06 2009-06-18 Kyowa Hakko Kirin Co., Ltd. Anti-A33 antibody
WO2006078072A1 (ja) 2005-01-21 2006-07-27 Kirin Beer Kabushiki Kaisha キメラ非ヒト動物およびその使用
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
US20100062984A1 (en) * 2007-01-25 2010-03-11 Rajiv Kumar Fgf-23 polypeptides
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
PT2502996T (pt) 2017-05-10
HUE031728T2 (en) 2017-07-28
EP2502996A2 (en) 2012-09-26
EP2128253A4 (en) 2010-03-10
FR18C1032I1 (es) 2018-08-31
DK3181691T3 (da) 2020-08-17
LT2502996T (lt) 2017-06-26
PL3181691T3 (pl) 2020-11-02
TW200902549A (en) 2009-01-16
HK1172917A1 (en) 2013-05-03
SI3181691T1 (sl) 2020-09-30
PT3181691T (pt) 2020-08-26
SI2502996T1 (sl) 2017-08-31
JPWO2008099969A1 (ja) 2010-05-27
KR20090114452A (ko) 2009-11-03
LTC2502996I2 (lt) 2019-05-10
CY2018021I2 (el) 2019-07-10
WO2008099969A1 (ja) 2008-08-21
CY1118835T1 (el) 2018-01-10
US20090148461A1 (en) 2009-06-11
CN101652476A (zh) 2010-02-17
AU2008215346B2 (en) 2013-01-10
NL300945I2 (en) 2020-05-13
NL300945I1 (en) 2018-08-15
EP2502996A3 (en) 2013-04-10
EP3181691B1 (en) 2020-07-15
KR101462291B1 (ko) 2014-11-14
FR18C1032I2 (fr) 2019-08-09
US9290569B2 (en) 2016-03-22
EP2128253A1 (en) 2009-12-02
EP3181691A1 (en) 2017-06-21
LT3181691T (lt) 2020-08-25
LUC00081I2 (es) 2018-10-01
ES2625823T3 (es) 2017-07-20
LTPA2018508I1 (lt) 2018-09-10
CA2677782C (en) 2016-07-26
PL2502996T3 (pl) 2017-07-31
CY1123240T1 (el) 2021-10-29
HRP20170548T1 (hr) 2017-08-25
ES2811318T3 (es) 2021-03-11
EP2128253B1 (en) 2014-12-03
PT2128253E (pt) 2015-02-04
CY2018021I1 (el) 2019-07-10
HUE050517T2 (hu) 2020-12-28
US10202446B2 (en) 2019-02-12
CN101652476B (zh) 2012-07-04
JP4800396B2 (ja) 2011-10-26
LUC00082I2 (es) 2018-10-01
NO2018025I1 (no) 2018-08-09
PL2128253T3 (pl) 2015-04-30
CN102702355B (zh) 2014-09-24
HK1140228A1 (en) 2010-10-08
AU2008215346A1 (en) 2008-08-21
CA2677782A1 (en) 2008-08-21
DK2128253T3 (en) 2015-01-05
US20160159895A1 (en) 2016-06-09
HUS1800034I1 (hu) 2018-09-28
DK2502996T3 (en) 2017-05-08
US7883705B2 (en) 2011-02-08
EP2502996B1 (en) 2017-03-29
CN102702355A (zh) 2012-10-03
US20190106485A1 (en) 2019-04-11
TWI422593B (zh) 2014-01-11
HRP20201266T1 (hr) 2021-02-05
US20110182913A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
PE20120429A1 (es) Proteinas de enlace de miostatina
ES2585480T3 (es) Anticuerpo anti-NR10 y uso del mismo
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
CY1120137T1 (el) Ενεσιμα σκευασματα βοτουλινικης τοξινης
ES2531385T3 (es) Formulación que comprende un anticuerpo contra la selectina P
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
PE20121393A1 (es) Analogo peptidico de oxintomodulina
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
NO20075927L (no) IL-21 varianter
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
ES2685823T3 (es) Anticuerpos antagonistas anti-CD40
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
CO6331346A2 (es) Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες
EA201001322A1 (ru) Вакцины против хламидиоза
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
PE20220570A1 (es) Anticuerpo anti-epha4 humano
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.